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The primary cilium of renal epithelia acts as a transducer of extracellular stimuli.
Polycystin (PC)1 is the protein encoded by the PKD1 gene that is responsible for the most
common and severe form of autosomal dominant polycystic kidney disease (ADPKD).
PC1 forms a complex with PC2 via their respective carboxy-terminal tails. Both proteins
are expressed in the primary cilia. Mutations in either gene affect the normal architecture
of renal tubules, giving rise to ADPKD. PC1 has been proposed as a receptor that
modulates calcium signals via the PC2 channel protein. The effect of PC1 dosage has been
described as the rate-limiting modulator of cystic disease. Reduced levels of PC1 or
disruption of the balance in PC1/PC2 level can lead to the clinical features of ADPKD,
without complete inactivation. Recent data show that ADPKD resulting from inactivation
of polycystins can be markedly slowed if structurally intact cilia are also disrupted at the
same time. Despite the fact that no single model or mechanism from these has been able
to describe exclusively the pathogenesis of cystic kidney disease, these ﬁndings suggest
the existence of a novel cilia-dependent, cyst-promoting pathway that is normally
repressed by polycystin function. The results enable us to rethink our current under-
standing of genetics and cilia signaling pathways of ADPKD.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
It has been reported that abnormalities in the structure or
function of primary cilia result in kidney cyst growth in animal
models and human genetic diseases collectively known as
ciliopathies [1–3]. Polycystin (PC)1 has been hypothesized to
form a mechanosensitive cation channel complex with PC2 in
the primary cilia [4–6]. Functional defects in this complex caused
by mutation of PKD1 or PKD2 result in autosomal dominant
polycystic kidney disease (ADPKD) [7,8]. Primary cilia are
membrane-enclosed hair-like projections from the apical surface
of renal epithelial cells, facing into the tubule lumen (Fig. 1).n Society of Nephrology. Publi
c-nd/4.0/).
nal Medicine, Section of
e, P.O. Box 208029, NewPrimary cilia are microtubule-based organelles that are ideally
positioned to detect extracellular stimuli and to transduce these
signals into the cell to elicit physiological responses [6,9].
Experimental evidence that ﬂow-mediated deﬂection of the cilia
induces an increase in intracellular calcium has fostered the
hypothesis that cilia may sense ﬂow in the kidney tubule lumens
[10–12]. Intraﬂagellar transport (IFT) is a general ciliary compo-
nent transport mechanism required for assembly and steady-
state maintenance of cilia [13,14]. IFT plays an additional role in
regulating cell-cycle progression independent of its function in
cilia formation [1]. Despite these data, there remains some lack of
clarity on the relationship between PCs and cilia function. Recent
studies have generated novel information regarding the genetic
and molecular implications of ADPKD, its pathogenesis, and new
potential strategies for targeted treatment. In this commentary,
new signaling activity of interconnectedness between primary
cilia and PCs, and dosage effects of PC are highlighted.shed by Elsevier. This is an open access article under the CC BY-NC-ND
Figure 1. PCs and cilia. (A) Renal tubular epithelium depicted as cuboidal cells with apical primary cilia projections subjected to luminal ﬂow.
(B) Schematic of 9 þ 0 primary cilia. As a microtubule-based structure that imports proteins via anterograde IFT and returns proteins to the cell body
via retrograde IFT transport. PC1 and PC2 reside in the cilium membrane and are hypothesized to subsume a local calcium signaling process that may
be modulated by mechanical or ligand stimuli. (C) Schematic representations of PC1 and PC2 showing their respective topologies and interaction via
coiled coil domains in their carboxy termini. PC1 has the properties of a receptor and undergoes cleavage at the indicated (red letters) GPS sites.
GPS site, whereas PC2 is a calcium channel of the TRP family. GPS, G protein coupled receptor proteolytic site; IFT, intraﬂagellar transport; PC, polycystin;
TRP, transient receptor potential. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Kidney Res Clin Pract 33 (2014) 73–7874ADPKDADPKD is a common, single-gene multi-system disorder. Its
prevalence at birth is between 1:400 and 1:1,000 and it affects
412 million people worldwide, without regard to sex or
ethnicity [5,7,8,15]. The disease is characterized by the devel-
opment of renal cysts and various extrarenal manifestations.
ADPKD results from excessive proliferation of renal tubular
epithelial cells and remodeling of surrounding structures,
giving rise to growth of epithelial-lined cysts accompanied
by ﬁbrosis and accumulation of extracellular matrix. As the
disease progresses, this leads to destruction of the normal
renal parenchyma, massive renal enlargement, deterioration of
renal function, and eventually renal failure in 450% of
affected individuals by late adulthood [5,15]. A two-hit model
has been proposed to explain the focal nature of renal cysts
and the variability in cyst size in both orthologous mouse
models and in humans [16–18]. In this model, a germline and a
somatic mutation inactivate the PKD alleles separately. The
ﬁrst hit, a germline mutation inherited from the affected
parent, is predisposing but not sufﬁcient for cyst formation.
The ﬁrst hit exists in all cells in the body. The second hit, a
somatic mutation in an individual cell, inactivates the normal
PKD1 or PKD2 allele, and when it occurs in kidney tubule cells,
is thought to cause abnormal focal proliferation and tissue
remodeling, giving rise to cyst formation [19,20]. Conditional
knockout of Pkd1 in mice indicates that the timing of the
somatic second hit mutation affects the severity of cyst
progression. Inactivation of Pkd1 in mice prior to a develop-
mental switch occurring prior to postnatal Day 13 results in
severely cystic kidneys within 3 weeks, whereas inactivation at
Day 14 and later results in cysts only after 5 months [21].
Multiple genetic mechanisms that result in an imbalance in
the expression of either PC1 or PC2 below a critical thresholdwithout complete loss can also cause cyst formation [22,23].
The presence of somatic PKD2 mutations detected in cystic
patients with PKD1 germline mutations and increased disease
severity in patients with heterozygous germline mutation in
both PKD1 and PKD2 offer further support for the two-hit
model and the dosage effect hypothesis for cyst formation
[24,25].ADPKD genes and proteins – PKD1, PKD2,
and PC1 and PC2
PKD1 mutations account for 85% of the clinically ascer-
tained disease burden. The PKD1 gene product, PC1, is a large
protein consisting of 4,302 amino acids with a large extra-
cellular amino terminus, 11 transmembrane domains, and a
short cytosolic carboxy terminus (Fig. 1C) [5,15]. PC1 is
possibly expressed in most nephron segments, despite expres-
sion at the tissue level being difﬁcult to determine due to its
low protein levels. At the subcellular level, it has been reported
that PCs are expressed in several subcellular compartments of
renal epithelial cells, remarkably primary cilia, lateral cell to
cell junctions, and the endoplasmic reticulum. Investigations
in other experiments have demonstrated that the localization
of PC fractions to primary cilia is thought to be required for the
function of cilia as mechanosensors [2,3,6,20,26].
PKD2, the gene mutated in 15% of polycystic kidney disease
cases, encodes PC2 [5,27]. PC2 has been described as a
nonselective, calcium-permeable cation channel belonging to
the transient receptor potential (TRP) polycystic subfamily of
TRP channels [28,29]. PC2 is an integral membrane protein
with six transmembrane segments, and both the amino and
carboxy termini face the cytoplasmic compartment [30,31].
PC2 contains several trafﬁcking motifs: the RVxP motif at the
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ciliary location of the protein [30], whereas a region at the
carboxy terminus may restrict the membrane location of PC2
to the endoplasmic reticulum and cilia. In the kidney, PC2 is
found in all nephron segments with the exception of the
glomeruli. PC1 is thought to function as a mechanosensor or
chemosensor at the primary cilia that coordinates the activity
of the PC2 calcium channel [15,32,33].
Disruption of primary cilia or mutations in cilia-associated
proteins leads to renal epithelial proliferation and cyst growth
in animal models and many human genetic diseases that are
classiﬁed as ciliopathies [2,3,34,35]. Primary cilia have an axone-
mal structure consisting of a circular array of nine pairs of
microtubules (9þ0 arrangement; Fig. 1B) [3]. Primary cilia are
single nonmotile projections on the apical surface of renal
epithelial cells toward the lumen [9]. They have a plasma
membrane but do not have subcellular organelles and protein-
synthetic capacity. Primary cilia, which are usually nonmotile, are
thought to serve either a chemosensory or mechanosensory
function [4,6]. The phenotypes of ciliopathies in mammals include
cystic kidneys, abnormal formation of the left–right body axis,
abnormalities in neural tube closure and patterning, skeletal
defects such as polydactyly, liver, and pancreatic cysts and ﬁbrosis,
and obesity [34,35]. In addition to their potential role as mechan-
osensors, primary cilia have important functions in sensing the
external environment and are essential to processes as diverse as
photoreception, olfaction, and developmental signaling [35].
Many cellular pathways have been proposed as effector
pathways in ciliary and cystic diseases. They include planar
cell polarity, Wnt, mammalian target of rapamycin, cyclic
adenosine monophosphate (cAMP), G-protein-coupled receptor,
cystic ﬁbrosis transmembrane conductance regulator, epidermal
growth factor receptor, mitogen-activated protein kinase
(MAPK), cellular calcium, and the cell cycle [5]. Experimental
evidence supports that cAMP stimulates MAPK/extracellular
signal-regulated kinase (ERK) signaling [36,37], and promotes
cyst growth. Functional loss of PC1 at the cilium results in
reduced cellular calcium signaling [6]. This in turn results in
increased adenylate cyclase and decreased phosphodiesterase
activity, leading to increased levels of intracellular cAMP.
Increased cAMP in cystic epithelium increases the activity of
protein kinase A, which can result in increased cell proliferation
and chloride-driven ﬂuid secretion; features associated with cyst
growth [5,36]. Lacking through all of these proposed functional
pathway hypotheses is an understanding of the relationship of
PCs with other ciliary component proteins and a clear deﬁnition
of the direct role of PC signaling within cilia.PC1 dosage in ADPKD
Studies on a possible gene-dosage effect for PCs have been
described in trans heterozygous states in mice [16]. Mutations in
Pkd1 resulting in reduction of functional PC1 have suggested that
reduced activity is sufﬁcient to cause cyst formation in some
situations [38–40]. Hence, PC1 dosage has been described as a
modulator of cystic disease. These authors generated an intronic
insertion of a neomycin cassette into Pkd1, which had a profound
effect on splicing efﬁciency. Although the hypomorphic Pkd1nl/nl
mice survive, they develop severe cystic kidneys from the collect-
ing duct, thick ascending limb, and distal tubules. Another study
[41] further supports that diminished expression of native PC1 is
sufﬁcient to induce renal cystic lesions of ADPKD. Studies havedemonstrated that 50% reduction in PC1 levels, as occurs in true
heterozygote ADPKD patients, does not lead to overt cyst forma-
tion, but 80% reduction may be sufﬁcient to result in a polycystic
phenotype [42]. A recent study demonstrating that the decrease in
the steady-state levels of PC1 that can be partially rescued in a
temperature-sensitive manner also points to the importance of
PC1 dosage in the modulation of cyst burden [43]. Separately, high
copy number Pkd1 transgenic mouse lines have reported the
presence of kidney cysts [44], suggesting that massively increased
dosage of PC1 also leads to cyst formation. Although the mechan-
ism for the latter is unknown, PC1 overexpression may generate
cysts by disrupting the steady-state balance of the PC1/PC2
complex, thereby altering its signaling [44].
A comprehensive study of the mechanisms underlying isolated
ADPKD has clearly demonstrated the central role of PC dosage in
kidney cyst formation [23,45]. The two genes responsible for
isolated polycystic liver disease, PRKCSH and SEC63, are both
involved in modulating protein biogenesis and quality control
for integral membrane and secreted proteins in the endoplasmic
reticulum. Inactivation of either of these genes results in inefﬁcient
maturation of the PCs and cyst formation in both the liver
and kidney in mouse models. This effect can be exacerbated by
reduced gene dosage for PKD1 or PKD2 [23]. Overexpression of
Pkd1, but not Pkd2, can overcome the tendency toward cyst
formation in Prkcsh and Sec63 mutants, thereby establishing PC1
as the rate-limiting component whose dosage determines both
the rate and extent of cyst formation in ADPKD [23,45]. In a proof
of principle experiment, inhibition of proteasomal degradation
using the proteasome inhibitor carﬁlzomib was able to ameliorate
polycystic disease progression in a manner analogous to increased
PC1 expression [23,45]. Based on these data, PC1 dosage is one of
the effector mechanisms of cyst formation in both mouse and
human ADPKD.Novel inter-relationship between primary cilia and PCs
Defects in primary cilia are associated with increased
proliferation of cells characteristic of polycystic kidney disease
[34,46]. IFT machinery is required to trafﬁc component pro-
teins into and out of cilia (Fig. 1B) [3,13,47]. Among the many
proteins delivered to cilia by IFT are PC1 and PC2, loss of either
of which results in ADPKD [4,48,49]. Kidney cysts also arise in
mice following the disruption of cilia by targeted inactivation
of genes encoding IFT components, such as the heterotrimeric
kinesin component Kif3a [50] and IFT proteins, Ift20 [47] and
Ift88 [11,51,52]. It is generally hypothesized that the primary
cilium of kidney epithelial cells acts as a sensory organelle and
that PC1 and PC2 form a receptor–channel sensory complex in
the cilium.
A recent study from our laboratory based on genetic
manipulation of polycystins and cilia in mutant mice has the
potential to recalibrate signiﬁcantly the concepts about the
inter-relationship between PC and cilia function [53]. Inactiva-
tion of PCs or cilia alone can lead to the formation of kidney
cysts. However, it has not been clear whether it is the loss of
PCs or persistence of intact cilia under conditions of loss of PCs
that is responsible for initiation of the signaling involved in
cyst growth. We evaluated these possible mechanisms by
using tissue-speciﬁc and inducible knockout of Pkd1 and
Pkd2 alone or in combination with knockout of Kif3a and
Ift20 in mouse models. We found that disruption of cilia
markedly delayed cyst growth caused by the loss of PCs.
PC1
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intact cilia + polycystin  
suppression of cyst growth 
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Figure 2. Schematic representation of the cilia dependent cyst promoting pathways in ADPKD. When PCs are normally expressed in cilia, renal
tubular architecture is preserved (left panel). When PCs are lost, intact cilia are responsible for signal (depicted by the star) that promotes rapid cyst
growth (right panel). When both PCs and cilia on non-functioning (center panel), indolent cyst growth results.
ADPKD, autosomal dominant polycystic kidney disease; PC, polycystin
Kidney Res Clin Pract 33 (2014) 73–7876Concomitant loss of Pkd1 or Pkd2 along with either Kif3a or
Ift20 resulted in much milder progression of polycystic disease
than was seen with inactivation of either PC alone (Fig. 2).
We further tested whether disease severity was affected by
a time-dependent persistence of cilia following PC loss. We
found that the shorter the time interval until cilia disappear-
ance following initial loss of PCs, the greater the protection
conferred against cyst progression.
Therefore, the severity of ADPKD is directly affected by the
duration of the persistence of cilia in the absence of PCs. These
ﬁndings suggest that PCs provide baseline tonic inhibition of
a cilium-dependent signal that promotes cyst growth when
unchecked following inactivation of PCs. As part of normal
physiology, this inhibitory function of PCs is likely altered
based on mechanical ﬂow or ligand-mediated regulation of
PC1 that is currently not understood. Neither reduced Pkd1 nor
increased Pkd1 gene dosage affects cyst formation following
cilia ablation, suggesting albeit not proving, that polycystic
disease following cilia inactivation occurs by PC-independent
mechanisms [53]. Taken together, the data show that loss of
PCs causes kidney cyst formation in a cilium-dependent
manner, but loss of cilia causes cyst formation independent
of PC function (Fig. 2).
The data suggest that the molecular mechanisms of the
cilium-dependent cyst promoting activity following loss of
polycystins are likely to be novel. We examined the activities
of the MAPK/ERK, mammalian target of rapamycin, and cAMP
pathways, all of which have been implicated in cystic mouse
models and therapeutic targets in human clinical trials, as
candidate effectors for this novel cilium-dependent process.
Although there was increased activity of both the MAPK/ERK
and cAMP pathways in cystic mice, both activities were
primarily conﬁned to distal nephron. These pathways were
therefore unable to account for the ubiquitous inhibition of
cyst growth observed following cilia ablation in all nephron
segments, including proximal tubule. Our data strongly sug-
gest the presence of a new, cilium-dependent cyst-promoting
pathway, which is suppressed by functional PCs. Our in vivo
studies prove the principle that targeting of the cilium-
dependent, PC-inhibited pathway will be effective in slowing
the progression of ADPKD. This novel cilium-dependent path-
way is now proposed as the central homeostatic mechanism ofpolycystins and cilium signaling in ADPKD. Deﬁning compo-
nents of this pathway will lead to improved targets for
potential therapies in ADPKD.Summary
The polycystin proteins are thought to be part of the
signaling system of the cilium required to maintain normal
renal structural and functional homeostasis. Both of the
functioning polycystins and intact cilia seem to be required
for tubular adaptation and maintaining the architecture of
renal epithelial tubules. The steady state of the physiological
roles of PC1 and PC2 regulates this cilium-dependent pathway
and elicits responses of tubule adaptation to either chemical or
mechanical signals. The cyst-suppressive role of polycystins
requires either mechanical or ligand-mediated activation to
affect calcium-dependent inhibition of cyst growth [46,54,55],
but the precise nature of these signals remains unknown. Our
ﬁndings strongly suggest that the components of cilium-
dependent cyst growth signals reside in cilia and require intact
cilia for activity. PC1 dosage can regulate cyst progression in
ADPKD by having inadequate levels to suppress fully the
cilium-dependent cyst-promoting pathway. This would
explain the hypothesis that cyst growth lies along a continuum
from physiological changes in tubule luminal diameter in
response to discrete stimuli, to slow cyst grow in the setting
of reduced PC1 function, and to more rapid cyst growth in the
setting of completely absent PC1 function. Altering PC1 levels
by chemical chaperone therapy may slow down cyst progres-
sion in a subset of patients in whom reduced, rather than
absent function is the cause of ADPKD. Our understanding of
ADPKD has evolved to include reduced PC dosage or PC loss as
a cause of ADPKD and have provided genetic evidence of the
existence of yet to be discovered novel targets for ADPKD
therapy that hold promise for the future wellbeing of these
patients with this complex disease.Conﬂicts of interest
None.
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